You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

 

Online download statistics by month:

Online download statistics by month: March 2023 to August 2025

AbstractFullPdf
Mar 2023728737277
Apr 2023449453201
May 2023319321101
Jun 202322622692
Jul 202317617778
Aug 202322722871
Sep 202320921071
Oct 202325825992
Nov 202322222475
Dec 202313013167
Jan 2024158158106
Feb 202414514860
Mar 202422322698
Apr 2024324327119
May 202418618793
Jun 202422223099
Jul 202427427682
Aug 202420320767
Sep 202434835181
Oct 202425625783
Nov 202419319572
Dec 202417418165
Jan 202524825376
Feb 202534834980
Mar 202522923185
Apr 202521822655
May 202514614888
Jun 202515716066
Jul 2025220
Aug 2025110
Total699970792600